We are live on ! Find out more
MAM

MPM Asset Management Portfolio holdings

AUM $44.5M Turnover 20%
1-Year Est. Return 47.28%
This Fund
S&P 500
This Quarter Est. Return
+16.09%
1 Year Est. Return
-47.28%
3 Year Est. Return
+5.89%
5 Year Est. Return
-18.52%
10 Year Est. Return
+3.53%
AUM
$306M
AUM Growth
+$8.32M
Cap. Flow
-$2.06M
Cap. Flow %
-0.67%
Top 10 Hldgs %
99.45%
Holding
14
New
–
Increased
3
Reduced
–
Closed
1
Avg Time Held
0.9 years
Top 10 Avg Time Held
0.8 years
Top 20 Avg Time Held
0.9 years

Top Buys

Rank Stock Value
1
SVRA icon
Savara
SVRA
+$1.22M
2
PETX
Aratana Therapeutics, Inc.
PETX
+$303K
3
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$5.28K

Top Sells

Rank Stock Value
1
PCRX icon
Pacira BioSciences
PCRX
+$3.58M

Sector Composition

Rank Sector Weight
1 Healthcare 91.58%
2 Miscellaneous 8.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RDUS icon
1
DELISTED
Radius Health, Inc.
RDUS
$122M 40.07%
5,831,253
– –
2014 Q2
1 quarter
EPZM
2
DELISTED
Epizyme, Inc
EPZM
$65.4M 21.41%
2,413,819
– –
2013 Q2
5 quarters
PTLA
3
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$30.9M 10.1%
1,220,672
– –
2013 Q2
5 quarters
TRIV
4
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$25.7M 8.42%
1,776,692
– –
2014 Q2
1 quarter
PETX
5
DELISTED
Aratana Therapeutics, Inc.
PETX
$21.3M 6.96%
2,118,845
+25,000
+1% +$303K
2013 Q2
5 quarters
ALT icon
6
Altimmune
ALT
$449M
$11.3M 3.7%
21,159
– –
2013 Q2
5 quarters
EIGR
7
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$11.2M 3.65%
2,372
+1
+0% +$5.28K
2014 Q1
2 quarters
HSTO
8
DELISTED
Histogen Inc. Common Stock
HSTO
$7.3M 2.39%
5,960
– –
2013 Q3
4 quarters
VSTM icon
9
Verastem
VSTM
$698M
$6.96M 2.28%
68,057
– –
2013 Q2
5 quarters
SVRA icon
10
Savara
SVRA
$978M
$1.43M 0.47%
36,455
+28,957
+386% +$1.22M
2014 Q1
2 quarters
ETRM
11
DELISTED
EnteroMedics Inc.
ETRM
$1.37M 0.45%
1,060
– –
2013 Q2
5 quarters
SGMO icon
12
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$243K 0.08%
22,487
– –
2013 Q4
3 quarters
MGNX icon
13
MacroGenics
MGNX
$211M
$66K 0.02%
3,168
– –
2013 Q4
3 quarters
PCRX icon
14
Pacira BioSciences
PCRX
$1.45B
– –
-39,025
Closed -$3.58M –

Similar funds

WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

MPM Asset Management's Q3 2014 Portfolio in Review

As of Q3 2014, MPM Asset Management held 14 positions worth $306M, up 2.8% from $297M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

MPM Asset Management's Q3 2014 filing shows 3 increased and 1 closed positions. The largest sale was Pacira BioSciences, an estimated $3.58M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Miscellaneous.

  • MPM Asset Management added most to Savara in Q3 2014, an estimated $1.22M increase.
  • MPM Asset Management fully exited Pacira BioSciences in Q3 2014, selling an estimated $3.58M.
  • MPM Asset Management's ten largest holdings make up 99% of its $306M portfolio in Q3 2014.
  • MPM Asset Management opened 0 new positions and closed 1 in Q3 2014.
  • MPM Asset Management's portfolio value rose 2.8% quarter-over-quarter to $306M.

Based on MPM Asset Management's 13F filing for Q3 2014, filed 23 Oct 2014.